Peripheral Blood Mononuclear Cell Gene Expression Remains Broadly Altered Years after Successful Interferon-Based Hepatitis C Virus Treatment

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Waldron, Paul Ravi ^a,b   Holodniy, Mark ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; HDAC4 PROTEIN, HUMAN; HISTONE DEACETYLASE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; REPRESSOR PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CEBPB GENE; CHRONIC HEPATITIS C; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FOS GENE; GENE; GENE EXPRESSION; HDAC4 GENE; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MYD88 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; TREATMENT FAILURE; TREATMENT RESPONSE; UPREGULATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPACIVIRUS; HEPATITIS, CHRONIC; IMMUNOLOGY; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MONONUCLEAR CELL; TREATMENT OUTCOME;

ADULT; AGED; ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS, CHRONIC; HISTONE DEACETYLASES; HUMANS; INTERFERON-ALPHA; LEUKOCYTES, MONONUCLEAR; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84947093099     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/958231     Document Type: Article

References (36)

1. K. Mohd Hanafiah, J. Groeger, A. D. Flaxman, and S. T. Wiersma, "Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody toHCV seroprevalence," Hepatology, vol. 57, no. 4, pp. 1333-1342, 2013.
2. K. N. Ly, J.Xing, R. M. Klevens, R. B. Jiles, and S.D.Holmberg, "Causes of death and characteristics of decedents with viral hepatitis, United States, 2010," Clinical Infectious Diseases, vol. 58, no. 1, pp. 40-49, 2014.
3. K. N. Ly, J. Xing, R. M. Klevens, R. B. Jiles, J. W. Ward, and S. D. Holmberg, "The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007," Annals of Internal Medicine, vol. 156, no. 4, pp. 271-278, 2012.
4. E. Chak, A. H. Talal, K. E. Sherman, E. R. Schiff, and S. Saab, "Hepatitis C virus infection in USA: an estimate of true prevalence," Liver International, vol. 31, no. 8, pp. 1090-1101, 2011.
5. E. Kenny-Walsh, "Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology ResearchGroup,"TheNewEngland Journal ofMedicine, vol. 340, no. 16, pp. 1228-1233, 1999.
6. D. L. Thomas, J. Astemborski, R. M. Rai et al., "The natural history of hepatitis C virus infection: host, viral, and environmental factors," Journal of the American Medical Association, vol. 284, no. 4, pp. 450-456, 2000.
7. D. L. Thomas, C. L. Thio, M. P. Martin et al., "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus," Nature, vol. 461, no. 7265, pp. 798-801, 2009.
8. M. G. Ghany, D. R. Nelson, D. B. Strader, D. L. Thomas, and L. B. Seeff, "An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases," Hepatology, vol. 54, no. 4, pp. 1433-1444, 2011.
9. M. G. Ghany, D. B. Strader, D. L. Thomas, and L. B. Seeff, "Diagnosis, management, and treatment of hepatitis C: an update," Hepatology, vol. 49, no. 4, pp. 1335-1374, 2009.
10. E. Lawitz, A. Mangia,D.Wyles et al., "Sofosbuvir for previously untreated chronic hepatitis C infection," The New England Journal of Medicine, vol. 368, no. 20, pp. 1878-1887, 2013.
11. A. J. van der Meer, B. J. Veldt, J. J. Feld et al., "Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis,"The Journal of the AmericanMedical Association, vol. 308, no. 24, pp. 2584-2593, 2012.
12. K. Hara,M.M. Rivera, C. Koh et al., "Sequence analysis of hepatitis c virus frompatients with relapse after a sustained virological response: relapse or reinfection?" The Journal of Infectious Diseases, vol. 209, no. 1, pp. 38-45, 2014.
13. M. Radkowski, J. F. Gallegos-Orozco, J. Jablonska et al., "Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C," Hepatology, vol. 41, no. 1, pp. 106-114, 2005.
14. H. I. Mohamed, H. K. Fath El-Bab, and A. M. Kamal, "HCV RNA in serum and peripheral blood mononuclear cells after successful interferon therapy," Hepato-Gastroenterology, vol. 58, no. 107-108, pp. 932-936, 2011.
15. T. N. Q. Pham,C. S.Coffin,N.D.Churchill, S. J. Urbanski, S. S. Lee, and T. I.Michalak, "Hepatitis C virus persistence after sustained virological response to antiviral therapy in patients with or without past exposure to hepatitis B virus," Journal of Viral Hepatitis, vol. 19, no. 2, pp. 103-111, 2012.
16. H. Zaghloul and W. El-Sherbiny, "Detection of occult hepatitis C and hepatitis B virus infections from peripheral blood mononuclear cells," Immunological Investigations, vol. 39, no. 3, pp. 284-291, 2010.
17. R. A. Zayed, E. Rushdy, and D. A. Saleh, "Detection of HCV RNA in the peripheral blood mononuclear cells of serum HCV RNA-negative Egyptian patients under interferon treatment," The American Journal of the Medical Sciences, vol. 340, no. 6, pp. 435-438, 2010.
18. D. Januszkiewicz-Lewandowska, J. Wysocki, M. Pernak et al., "Presence of hepatitis C virus (HCV)-RNA in peripheral blood mononuclear cells in HCV serum negative patients during interferon and ribavirin therapy," Japanese Journal of Infectious Diseases, vol. 60, no. 1, pp. 29-32, 2007.
19. A. Y. Chen, M. Zeremski, R. Chauhan, I. M. Jacobson, A. H. Talal, and T. I. Michalak, "Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis Cwith standard pegylated interferon α-2b and ribavirin therapy," PLoS ONE, vol. 8, no. 11, Article ID e80078, 2013.
20. F. Bernardin, L. Tobler, I.Walsh, J.D.Williams,M. Busch, and E. Delwart, "Clearance of hepatitis C virus RNA from the peripheral blood mononuclear cells of blood donors who spontaneously or therapeutically control their plasma viremia," Hepatology, vol. 47, no. 5, pp. 1446-1452, 2008.
21. K. Fujiwara, R. D. Allison, R. Y. Wang et al., "Investigation of residual hepatitis C virus in presumed recovered subjects," Hepatology, vol. 57, no. 2, pp. 483-491, 2013.
22. L. E.Kushner, A. M.Wendelboe, L. C. Lazzeroni et al., "Immune biomarker differences and changes comparing HCV monoinfected, HIV/HCV co-infected, and HCV spontaneously cleared patients," PLoS ONE, vol. 8, no. 4, Article ID e60387, 2013.
23. G. M. Sousa, I. S. Oliveira, L. J. O. Andrade, M. L. B. Sousa-Atta, R. Paraná, and A.M.Atta, "Serum levels ofTh17 associated cytokines in chronic hepatitis C virus infection," Cytokine, vol. 60, no. 1, pp. 138-142, 2012.
24. T. N. Q. Pham, S. E. Mercer, and T. I. Michalak, "Chronic hepatitis C and persistent occult hepatitis C virus infection are characterized by distinct immune cell cytokine expression profiles," Journal of Viral Hepatitis, vol. 16, no. 8, pp. 547-556, 2009.
25. M. Radkowski, J. Opoka-Kegler, K. C. Cortes et al., "Evidence for immune activation in patientswith residual hepatitis C virus RNA long after successful treatment with IFN and ribavirin," The Journal of General Virology, vol. 95, no. 9, pp. 2004-2009, 2014.
26. A. K. Barcz, J. E.Gomez, B. B. Kaufmann et al., "RNA signatures allow rapid identification of pathogens and antibiotic susceptibilities," Proceedings of the National Academy of Sciences of theUnited States of America, vol. 109, no. 16, pp. 6217-6222, 2012.
27. J. J. Chang,M.Woods, R. J. Lindsay et al., "Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication," The Journal of Infectious Diseases, vol. 208, no. 5, pp. 830-838, 2013.
28. A. Vallet-Pichard, V. Mallet, B. Nalpas et al., "FIB-4: an inexpensive and accuratemarker of fibrosis inHCVinfection.Comparison with liver biopsy and fibrotest," Hepatology, vol. 46, no. 1, pp. 32-36, 2007.
29. M. E. Charlson, P. Pompei, K. L. Ales, and C. R. MacKenzie, "A new method of classifying prognostic comorbidity in longitudinal studies: development and validation," Journal of Chronic Diseases, vol. 40, no. 5, pp. 373-383, 1987.
30. J. Hess, P. Angel, and M. Schorpp-Kistner, "AP-1 subunits: quarrel and harmony among siblings," Journal of Cell Science, vol. 117, no. 25, pp. 5965-5973, 2004.
31. K. A. Fitzgerald, E. M. Palsson-Mcdermott, A. G. Bowie et al., "Mal (MyD88-adapter-like) is required for toll-like recepfor-4 signal transduction," Nature, vol. 413, no. 6851, pp. 78-83, 2001.
32. M. Saraiva and A. O'Garra, "The regulation of IL-10 production by immune cells," Nature Reviews Immunology, vol. 10,no. 3, pp. 170-181, 2010.
33. W. Glenisson, V. Castronovo, and D. Waltregny, "Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation," Biochimica et Biophysica Acta - Molecular Cell Research, vol. 1773, no. 10, pp. 1572-1582, 2007.
34. M. T. Dill, Z. Makowska, G. Trincucci et al., "Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation," The Journal of Clinical Investigation, vol. 124, no. 4, pp. 1568-1581, 2014.
35. J. L. Casado, M. A. Esteban, S. Bañón et al., "Fibrosis regression explains differences in outcome in HIV-/HCV-coinfected patients with cirrhosis after sustained virological response," Digestive Diseases and Sciences, 2015.
36. H.W. Zimmermann, S. Seidler, N. Gassler et al., "Interleukin-8 is activated in patientswith chronic liver diseases and associated with hepaticmacrophage accumulation in human liver fibrosis," PLoS ONE, vol. 6, no. 6, Article ID e21381, 2011.